Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects

This report describes phase 1 clinical trials performed to assess interactions of oral isavuconazole at the clinically targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P450 (CY...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacol Drug Dev
Autors principals: Yamazaki, Takao, Desai, Amit, Goldwater, Ronald, Han, David, Howieson, Corrie, Akhtar, Shahzad, Kowalski, Donna, Lademacher, Christopher, Pearlman, Helene, Rammelsberg, Diane, Townsend, Robert
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5297975/
https://ncbi.nlm.nih.gov/pubmed/27273149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.281
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars